Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

Rodrigo Cartin-Ceba; Michael Halank; Hossein Ardeschir Ghofrani; Marc Humbert; John Mattson; Arno Fritsch; Michael Joseph Krowka

doi:10.1177/2045894018769305

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

Rodrigo Cartin-Ceba, Michael Halank, Hossein Ardeschir Ghofrani, Marc Humbert, John Mattson, Arno Fritsch, Michael Joseph Krowka

Pulmonary and Critical Care Medicine

Research output: Contribution to journal › Letter

5 Scopus citations

Abstract

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.

Original language	English (US)
Journal	Pulmonary Circulation
Volume	8
Issue number	2
DOIs	https://doi.org/10.1177/2045894018769305
State	Published - Apr 1 2018

Fingerprint

Keywords

portal hypertension
pulmonary arterial hypertension
soluble guanylate cyclase stimulator

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Cite this

Cartin-Ceba, R., Halank, M., Ghofrani, H. A., Humbert, M., Mattson, J., Fritsch, A., & Krowka, M. J. (2018). Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies. Pulmonary Circulation, 8(2). https://doi.org/10.1177/2045894018769305

@article{6bb2eff3434e4833bf75bf3e0179b248,

title = "Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies",

abstract = "In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.",

keywords = "portal hypertension, pulmonary arterial hypertension, soluble guanylate cyclase stimulator",

author = "Rodrigo Cartin-Ceba and Michael Halank and Ghofrani, {Hossein Ardeschir} and Marc Humbert and John Mattson and Arno Fritsch and Krowka, {Michael Joseph}",

year = "2018",

month = apr,

day = "1",

doi = "10.1177/2045894018769305",

language = "English (US)",

volume = "8",

journal = "Pulmonary Circulation",

issn = "2045-8932",

publisher = "University of Chicago Press",

number = "2",

}

TY - JOUR

T1 - Riociguat treatment for portopulmonary hypertension

T2 - a subgroup analysis from the PATENT-1/-2 studies

AU - Cartin-Ceba, Rodrigo

AU - Halank, Michael

AU - Ghofrani, Hossein Ardeschir

AU - Humbert, Marc

AU - Mattson, John

AU - Fritsch, Arno

AU - Krowka, Michael Joseph

PY - 2018/4/1

Y1 - 2018/4/1

N2 - In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.

AB - In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.

KW - portal hypertension

KW - pulmonary arterial hypertension

KW - soluble guanylate cyclase stimulator

UR - http://www.scopus.com/inward/record.url?scp=85049873206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049873206&partnerID=8YFLogxK

U2 - 10.1177/2045894018769305

DO - 10.1177/2045894018769305

M3 - Letter

AN - SCOPUS:85049873206

VL - 8

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 2

ER -

Access to Document

10.1177/2045894018769305